Optimal timing maximises Paxlovid benefits for treating COVID-19

Researchers have described the optimal timing for COVID-19 patients to take the antiviral, Paxlovid, to get the most benefit from the treatment, according to a study published April 16 in eLife. The findings suggest that taking Paxlovid three to five days after COVID-19 symptoms emerge may maximise the drug's ability to reduce viral loads, minimise viral spread and reduce viral rebound.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news